News

Immix Biopharma prices 125 million dollar stock offering

Finance

Immix Biopharma prices 125 million dollar stock offering

13 sourcesUpdated Sep 30, 2026

Sponsored

In this story:

More on this story

Back to News

Finance

Stocks Weighed Down by Oil and Surging Yields

U.S. stock futures were mixed to slightly lower as rising Treasury yields and hawkish Fed signals weighed on sentiment, while investors also watched U.S.-China and Iran developments. Upcoming economic reports and corporate news, including Micron results and Tesla sales, were among the catalysts in focus.

81 sources

Tech

Anthropic Files for IPO with $42B Loss and $518B Spending Plans

Anthropic's IPO filing shows a $42 billion 2025 net loss and $518 billion in infrastructure plans, with a potential valuation above $2 trillion.

Does this breakdown look right?

Sponsored

How it spread

Broke stocktitan.net · Sep 29, 7:05 AM ETRight within the hourCenter +35h13 sources +35h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

How each side headlines it

Left· 0 sources

No left coverage yet — a bubble gap.

Center· 1 source

“Immix Biopharma Closes $125 Million Stock Offering”

MarketScreener · Sep 30, 2026

Right· 1 source

“Immix Biopharma prices $125M stock offering (IMMX:NASDAQ)”

Seeking Alpha · Sep 29, 2026

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

255 sources

Sponsored

Business

Short Interest Rises Across Four Stocks, Up 105%-366%

Short interest rose sharply in September across Laramide Resources, MIRA Pharmaceuticals, Universe Pharmaceuticals and VIDA Global, increasing 105.5%, 118.1%, 154.7% and 365.7%, respectively, by Sept. 15. The short positions represented a wide range of trading pressure: Laramide had a 173.6-day days-to-cover ratio, while the other three had ratios of 0.1 to 0.2 days.

94 sources